Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug Ozempic.) Eli Lilly is hot on Novo Nordisk's heels with its new obesity drug Zepbound. Pfizer…#novonordisk #elililly #pfe #lilly #pf07976016 #danuglipron #pfizer #nash #vikingtherapeutics #seagen
Source: Reuters: Health - Category: Consumer Health News Source Type: news